Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
AstraZeneca
Mallinckrodt
Boehringer Ingelheim
Colorcon
McKesson

Last Updated: December 12, 2019

DrugPatentWatch Database Preview

Litigation Details for Cephalon Inc. v. Watson Pharmaceuticals Inc. (D. Del. 2009)

Join the DrugPatentWatch Referral Program
Get access to a free drug patent landscape report or a free one-month subscription

« Back to Dashboard

Cephalon Inc. v. Watson Pharmaceuticals Inc. (D. Del. 2009)

Docket   Start Trial Date Filed 2009-09-25
Court District Court, D. Delaware Date Terminated 2011-03-24
Cause 35:271 Patent Infringement Assigned To Sue Lewis Robinson
Jury Demand Plaintiff Referred To
Parties CEPHALON INC.; WATSON LABORATORIES INC.; WATSON PHARMA INC.; WATSON PHARMACEUTICALS INC.
Patents 4,671,953; 6,200,604; 6,264,981; 6,974,590; 7,834,020
Attorneys Laura D. Hatcher; Steven J. Fineman; William J. Marsden , Jr.
Link to Docket External link to docket
Small Molecule Drugs cited in Cephalon Inc. v. Watson Pharmaceuticals Inc.
The small molecule drugs covered by the patents cited in this case are   Start Trial ,   Start Trial ,   Start Trial , and   Start Trial .
Biologic Drugs cited in Cephalon Inc. v. Watson Pharmaceuticals Inc.
The biologic drug covered by the patents cited in this case is   Start Trial .

Details for Cephalon Inc. v. Watson Pharmaceuticals Inc. (D. Del. 2009)

Date Filed Document No. Description Snippet Link To Document
2009-09-25 1 Complaint 25 delivery is disclosed in U.S. Pat. No. 4,671,953 to Stanley, …infringement of United States Patent No. 6,264,981 B1 ("the '981 patent") under 28 U.S.C. §§… THE PATENT IN SUIT 15. On July 24, 2001, the '981 patent titled "Oral…Application prior to patent expiry would constitute infringement of the '981 patent. 21. …United States Patent (10) Patent No.: External link to document
2010-09-30 155 claims of U.S, Patent Nos. 6,264,981 (“the ’981 patent”), 6,200,604 (“the ’604 patent”], and 6,974,590…quot; The Orange Book Patents ....................... 287 IV, THE ORANGE BOOK PATENTS ARE N()'I` ENABLEI…regarding the Orange Bool< patents, Plaintifts argue: “[A]s the Khan]cari patents detaii, the probiem addressed…OF THE ’981 PATENT ARE OBV'IOUS. To invalidate the asserted claims of the ’981 patent, the Court …same “solid solution" as the ’98| patent because both patents disclose the same manufacturing process External link to document
2011-03-24 194 '981 patent are obvious in view of Stanley in combination with U.S. Patent No. 4,671,953 (the "… U.S. Patent Nos. 6,200,604 (lithe '604 patent") and 6,974,590 (lithe '590 patent")…quot;) is the owner of U.S. Patent No. 6,264,981 ("the '981 patent"). Cephalon is the holder… (collectively, the "Khankari patents"), which patents were listed in the Orange Book in connection…Act for a drug claimed in a patent or the use of which is claimed in a patent[.]"). to 28 U.S.C. § External link to document
2011-03-24 197 the Commissioner of Patents and Trademarks for Patent/Trademark Number(s) 6,264,981 B1. (nmf) (Entered:…2009 24 March 2011 1:09-cv-00724-SLR Patent Plaintiff District Court, D. External link to document
2009-11-12 25 for infringement of United States Patent No. 6,264,981 (“the ’981 patent”). Plaintiff admits that this Court…Judgment of Noninfringement of United States Patent No. 6,264,981 B1 42. Plaintiff incorporates by reference…Judgment of Noninfringement of United States Patent No. 6,264,981 B1 45. Plaintiff incorporates by reference… Judgment of Invalidity of United States Patent No. 6,264,981 Bl 47. Plaintiff incorporates by reference…Defendants’ liability for infringement of the ’981 patent. Plaintiff denies the remaining allegations of External link to document
>Date Filed >Document No. >Description >Snippet >Link To Document

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Merck
Colorcon
Harvard Business School
McKesson
Moodys
Johnson and Johnson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.